Champions Oncology (CSBR) Cash from Investing Activities (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Cash from Investing Activities of -$14000.0 in Q1 2026, up 94.21% quarter-over-quarter from -$242000.0 in Q4 2025, and up 66.67% on a YoY basis from -$8400.0 in Q1 2025.
Champions Oncology (CSBR) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Champions Oncology's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$14000.0 for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 66.67% year-over-year to -$14000.0; the TTM figure through Jan 2026 stood at -$555000.0 (down 317.29% YoY), while the FY2025 annual figure was -$389000.0, up 53.47% from the prior year.
- Cash from Investing Activities was -$14000.0 for Q1 2026 at Champions Oncology, up from -$242000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $3000.0 in Q2 2024 to a low of -$760000.0 in Q2 2023.
- Historically, Cash from Investing Activities has averaged -$331875.0 across 5 years, with a median of -$247500.0 in 2025.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities soared 100.39% in 2024, then tumbled 8533.33% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at -$604000.0 in 2022, then surged by 86.92% to -$79000.0 in 2023, then decreased by 18.99% to -$94000.0 in 2024, then sank by 157.45% to -$242000.0 in 2025, then surged by 94.21% to -$14000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$14000.0 (Q1 2026), -$242000.0 (Q4 2025), and -$46000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 579,519.10 |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | -14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -14,000.00 |
| Jan 31, 2026 | -14,000.00 |
| Oct 31, 2025 | -242,000.00 |
| Oct 31, 2025 | -242,000.00 |
| Jul 31, 2025 | -46,000.00 |
| Jul 31, 2025 | -46,000.00 |
| Apr 30, 2025 | -253,000.00 |
| Apr 30, 2025 | -253,000.00 |
| Jan 31, 2025 | -42,000.00 |
| Jan 31, 2025 | -42,000.00 |
| Oct 31, 2024 | -94,000.00 |
| Oct 31, 2024 | -94,000.00 |
| Apr 30, 2024 | 3,000.00 |
| Apr 30, 2024 | 3,000.00 |
| Jan 31, 2024 | -92,000.00 |
| Jan 31, 2024 | -92,000.00 |
| Oct 31, 2023 | -79,000.00 |
| Oct 31, 2023 | -79,000.00 |
| Jul 31, 2023 | -668,000.00 |
| Jul 31, 2023 | -668,000.00 |